CytoMed Therapeutics Limited (GDTC)
NASDAQ: GDTC · Real-Time Price · USD
1.060
+0.010 (0.95%)
At close: Mar 9, 2026, 4:00 PM EDT
1.040
-0.020 (-1.89%)
After-hours: Mar 9, 2026, 7:12 PM EDT
CytoMed Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Mar '26 Mar 9, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Market Capitalization | 12 | 39 | 56 | - | - | - | |
| Market Cap Growth | -61.45% | -30.55% | - | - | - | - | |
| Enterprise Value | 10 | 35 | 49 | - | - | - | |
| Last Close Price | 1.06 | 3.40 | 4.90 | - | - | - | |
| PS Ratio | 21.34 | 106.38 | 146.86 | - | - | - | |
| PB Ratio | 2.18 | 5.92 | 6.63 | - | - | - | |
| P/TBV Ratio | 2.20 | 6.04 | 6.64 | - | - | - | |
| EV/Sales Ratio | 18.10 | 93.59 | 127.72 | - | - | - | |
| Debt / Equity Ratio | 0.07 | 0.05 | 0.04 | 7.20 | 1.26 | 6.27 | |
| Net Debt / Equity Ratio | -0.33 | -0.50 | -0.76 | 4.50 | 0.28 | 4.31 | |
| Net Debt / EBITDA Ratio | 0.74 | 1.61 | 2.47 | -1.80 | -0.52 | -2.00 | |
| Net Debt / FCF Ratio | 0.59 | 1.10 | 2.38 | -1.41 | -0.32 | -1.87 | |
| Asset Turnover | 0.08 | 0.05 | 0.06 | 0.06 | 0.02 | 0.02 | |
| Inventory Turnover | 0.07 | 0.04 | 0.01 | 0.02 | 0.01 | 0.03 | |
| Quick Ratio | 4.31 | 8.39 | 12.83 | 0.39 | 0.86 | 0.35 | |
| Current Ratio | 5.81 | 9.89 | 14.08 | 0.60 | 1.12 | 0.54 | |
| Return on Equity (ROE) | -42.33% | -24.86% | -69.87% | -197.08% | -133.79% | -161.72% | |
| Return on Assets (ROA) | -22.85% | -17.44% | -27.30% | -20.55% | -21.98% | -24.47% | |
| Return on Capital Employed (ROCE) | -46.00% | -33.10% | -33.00% | -175.10% | -55.30% | -120.90% | |
| Earnings Yield | -23.57% | -4.70% | -5.54% | - | - | - | |
| FCF Yield | -25.58% | -7.68% | -4.81% | - | - | - | |
| Buyback Yield / Dilution | - | -8.56% | -34.30% | -14.14% | -17.59% | -6.22% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.